Dr. Martin Markowitz, MD

Infectious Disease New York, NY Male
NPI: 1790987030
Total Payments
$112,821
2023 Payments
$3,493
Companies
5
Transactions
123

Payment Breakdown by Category

Consulting$51,371 (45.5%)
Other$41,300 (36.6%)
Travel$15,880 (14.1%)
Food & Beverage$3,411 (3.0%)
Research$859.09 (0.8%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $51,371 14 45.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,300 13 36.6%
Travel and Lodging $15,880 36 14.1%
Food and Beverage $3,411 51 3.0%
Unspecified $859.09 9 0.8%

Payments by Type

General
$111,962
114 transactions
Research
$859.09
9 transactions

Top Paying Companies

Company Total Records Latest Year
Merck Sharp & Dohme Corporation $39,170 40 $0 (2018)
Gilead Sciences, Inc. $38,169 47 $0 (2019)
Theratechnologies Inc. $17,976 6 $0 (2023)
ViiV Healthcare Company $16,967 26 $0 (2018)
GlaxoSmithKline, LLC. $538.49 4 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2023 $3,493 1 Theratechnologies Inc. ($3,493)
2022 $11,277 3 Theratechnologies Inc. ($11,277)
2021 $3,206 2 Theratechnologies Inc. ($3,206)
2019 $15,386 17 Gilead Sciences, Inc. ($15,386)
2018 $40,343 38 Merck Sharp & Dohme Corporation ($23,898)
2017 $39,115 62 Merck Sharp & Dohme Corporation ($15,272)

All Payment Transactions

123 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
09/19/2023 Theratechnologies Inc. TROGARZO (Drug) Consulting Fee Cash or cash equivalent $3,493.00 General
Category: HIV
10/06/2022 Theratechnologies Inc. TROGARZO (Drug) Consulting Fee Cash or cash equivalent $5,075.00 General
Category: HIV
07/18/2022 Theratechnologies Inc. TROGARZO (Drug) Consulting Fee Cash or cash equivalent $3,353.00 General
Category: HIV
03/08/2022 Theratechnologies Inc. TROGARZO (Drug) Consulting Fee Cash or cash equivalent $2,849.00 General
Category: HIV
10/21/2021 Theratechnologies Inc. TROGARZO (Drug) Consulting Fee Cash or cash equivalent $1,018.50 General
Category: HIV
07/16/2021 Theratechnologies Inc. TROGARZO (Drug) Consulting Fee Cash or cash equivalent $2,187.50 General
Category: HIV
10/30/2019 Gilead Sciences, Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,500.00 General
10/28/2019 Gilead Sciences, Inc. — Food and Beverage In-kind items and services $122.16 General
08/22/2019 Gilead Sciences, Inc. Biktarvy (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,500.00 General
Category: HIV
08/21/2019 Gilead Sciences, Inc. Biktarvy (Drug) Food and Beverage In-kind items and services $124.99 General
Category: HIV
07/18/2019 Gilead Sciences, Inc. Biktarvy (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,500.00 General
Category: HIV
07/17/2019 Gilead Sciences, Inc. Biktarvy (Drug) Food and Beverage In-kind items and services $119.05 General
Category: HIV
07/17/2019 Gilead Sciences, Inc. Biktarvy (Drug) Travel and Lodging In-kind items and services $44.07 General
Category: HIV
04/18/2019 Gilead Sciences, Inc. — Travel and Lodging In-kind items and services $102.35 General
04/18/2019 Gilead Sciences, Inc. — Food and Beverage In-kind items and services $42.68 General
04/12/2019 Gilead Sciences, Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,300.00 General
03/28/2019 Gilead Sciences, Inc. — Travel and Lodging In-kind items and services $581.40 General
03/28/2019 Gilead Sciences, Inc. — Travel and Lodging In-kind items and services $375.06 General
03/28/2019 Gilead Sciences, Inc. — Travel and Lodging In-kind items and services $343.00 General
03/28/2019 Gilead Sciences, Inc. — Food and Beverage In-kind items and services $48.82 General
03/25/2019 Gilead Sciences, Inc. Biktarvy (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,500.00 General
Category: HIV
03/21/2019 Gilead Sciences, Inc. Biktarvy (Drug) Food and Beverage In-kind items and services $124.99 General
Category: HIV
03/19/2019 Gilead Sciences, Inc. Viread (Drug) Food and Beverage In-kind items and services $57.70 General
Category: HBV
12/18/2018 Gilead Sciences, Inc. Biktarvy (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,500.00 General
Category: HIV
12/10/2018 Gilead Sciences, Inc. Biktarvy (Drug) Food and Beverage In-kind items and services $33.32 General
Category: HIV
123…5»

Research Studies & Clinical Trials

Study Name Company Amount Records
A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect GlaxoSmithKline, LLC. $538.49 4
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY ViiV Healthcare Company $188.53 2
A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect ViiV Healthcare Company $132.07 3

About Dr. Martin Markowitz, MD

Dr. Martin Markowitz, MD is a Infectious Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1790987030.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Markowitz, MD has received a total of $112,821 in payments from pharmaceutical and medical device companies, with $3,493 received in 2023. These payments were reported across 123 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($51,371).

Practice Information

  • Specialty Infectious Disease
  • Location New York, NY
  • Active Since 05/31/2007
  • Last Updated 07/08/2007
  • Taxonomy Code 207RI0200X
  • Entity Type Individual
  • NPI Number 1790987030

Products in Payments

  • TROGARZO (Drug) $17,976
  • Biktarvy (Drug) $13,184
  • TIVICAY (Drug) $7,956
  • DELSTRIGO (Drug) $5,675
  • Genvoya (Drug) $4,331
  • ISENTRESS (Drug) $621.35
  • Viread (Drug) $57.70

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Infectious Disease Doctors in New York

Sian Jones, Md, MD

Infectious Disease — Payments: $349,236

Infectious Disease $349,236

Dr. David Bekhor, Md, MD

Infectious Disease — Payments: $309,279

Infectious Disease $309,279

Genovefa Papanicolaou, Md, MD

Infectious Disease — Payments: $183,179

Infectious Disease $183,179

Dr. Michelle Cespedes, M.d, M.D

Infectious Disease — Payments: $136,443

Infectious Disease $136,443

Mr. Jose Cortes, M.d, M.D

Infectious Disease — Payments: $123,792

Infectious Disease $123,792

Dr. Thomas Walsh, M.d, M.D

Infectious Disease — Payments: $112,227

Infectious Disease $112,227